Actively Recruiting
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Led by Mayo Clinic · Updated on 2026-05-01
30
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
A
Alcon Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the 24-hour effect on intraocular pressure IOP reduction of a fixed combination of netarsudil and latanoprost compared to latanoprost alone in adults aged 18 years and older with open angle glaucoma or ocular hypertension. This study is a phase 4, double-masked, paired-contralateral trial aimed at understanding how these treatments compare when applied in each eye of the same subject. Participants will receive netarsudil-latanoprost fixed combination eye drops in one eye and latanoprost eye drops in the other eye, each dosed once daily at night for 14 consecutive days. The total participation time may extend up to 10 weeks to include any necessary washout from prior treatments. This design allows direct comparison of the two treatments within the same individual. During the study, participants will undergo various eye examinations including visual field testing, optical coherence tomography, and dilated fundus exams to assess IOP changes. Researchers will monitor IOP changes over 24 hours, focusing on mean IOP reduction, nighttime and daytime IOP variations after two weeks of treatment. Safety and adherence will be tracked throughout, with total study involvement lasting up to 10 weeks including screening and washout periods.
CONDITIONS
Brief Title
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of ocular hypertension or mild-to-moderate open angle glaucoma in both eyes
- Intraocular pressure of 18 mmHg or higher but less than 34 mmHg in both eyes
- Able and willing to provide signed informed consent
- Able to cooperate with study examinations and attend all visits
- Contact lens wearers must remove lenses at least 24 hours before visits
- Best-corrected visual acuity of +0.4 logMAR units (about 20/50) or better in each eye
You will not qualify if you...
- Narrow angles (3 quadrants Grade 2 or less), angle closure, or history of angle closure in either eye
- Severe glaucomatous damage
- Difference in intraocular pressure between eyes greater than 4 mmHg at baseline
- Use of more than two ocular pressure-lowering medications within 30 days before screening
- Chronic or recurrent inflammatory eye diseases
- Recent ocular infection or inflammation within 3 months
- Recent ocular trauma (except minor corneal abrasion) within 6 months
- Significant retinal diseases such as severe diabetic retinopathy or macular degeneration
- Corneal changes preventing reliable measurements
- High myopia greater than -6.00D or hyperopia greater than +2.00D
- Central corneal thickness outside 480 to 620 micrometers
- Previous eye surgeries except uncomplicated cataract surgery
- Previous glaucoma surgeries or laser treatments except selective laser trabeculoplasty over 6 months ago
- Severe dry eye
- Use of ocular medications within 30 days except study-required washout and lubricating drops
- Known allergy to study medication components
- Significant systemic diseases interfering with the study
- Participation in other interventional studies within 30 days
- Recent or anticipated changes in systemic medications affecting eye pressure
- Women who are pregnant, nursing, planning pregnancy, or not using acceptable birth control
- Known allergies or contraindications to study medication ingredients
Research Team
B
Bridgette Halder
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here